skip to Main Content
placeholder

Imaging Endpoints Congratulates Novartis on its FDA approval of Locametz® and Pluvicto™ for Selection and Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

March 31, 2022 - Imaging Endpoints congratulates Novartis for its recent Food and Drug Administration (FDA) approval of Locametz® and Pluvicto™. The FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen…   Read More

Back To Top